scispace - formally typeset
M

Michael B. Rothberg

Researcher at Cleveland Clinic

Publications -  341
Citations -  11545

Michael B. Rothberg is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Medicine & Retrospective cohort study. The author has an hindex of 50, co-authored 294 publications receiving 9943 citations. Previous affiliations of Michael B. Rothberg include Baystate Medical Center & Tufts University.

Papers
More filters
Journal ArticleDOI

Public Reporting and Pay for Performance in Hospital Quality Improvement

TL;DR: Hospitals engaged in both public reporting and pay for performance achieved modestly greater improvements in quality than did hospitals engaged only in public reporting.
Journal ArticleDOI

The Clinically Inapparent Adrenal Mass: Update in Diagnosis and Management

TL;DR: A comprehensive update of the diagnostic and therapeutic approaches focusing on endocrine and radiological features as well as surgical options for clinically inapparent adrenal masses is provided.
Journal ArticleDOI

Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007.

TL;DR: The increase in the number of hospitalizations for severe sepsis coupled with declining in-hospital mortality and declining geometric mean cost per case may reflect improvements in care or increases in discharges to skilled nursing facilities; however, these findings more likely represent changes in documentation and hospital coding practices that could bias efforts to conduct national surveillance.
Journal ArticleDOI

Complications of Viral Influenza

TL;DR: During influenza season, treatment of pneumonia should include empiric coverage for this pathogen, and increasing resistance to amantadine and perhaps neuraminidase inhibitors underscores the need for novel prevention and treatment strategies.
Journal ArticleDOI

Warfarin plus Aspirin after Myocardial Infarction or the Acute Coronary Syndrome: Meta-Analysis with Estimates of Risk and Benefit

TL;DR: A meta-analysis of randomized trials of warfarin therapy for individuals and the expected benefit for groups at varying risk for cardiovascular disease and bleeding found that patients at the highest risk for recurrent cardiovascular events should derive the most benefit, which may be offset in those with increased bleeding risk.